Drug intelligence / Profile preview

Macula 30+

Development stage: Unknown
Lead developer: Quantum Health
Modality: Small Molecules
Administration: Oral

Overview

Macula 30+ is a multi-ingredient dietary supplement developed by Quantum Health to support macular health and visual performance, particularly in aging populations. Formulated by eye health expert Dr. James Stringham, the supplement features a 5:1 ratio of lutein to zeaxanthin (sourced from Lutemax 2020) alongside omega-3 fatty acids (DHA and EPA), vitamin C, vitamin E, and zinc. It is designed to maintain macular pigment optical density, improve glare recovery and low-light vision, and provide protection against blue light. As a nutraceutical, it functions by providing essential carotenoids and antioxidants that accumulate in the retina to neutralize free radicals and filter high-energy light.

Brand names: Macula 30+

Beyond the preview

Go deeper on Macula 30+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macula 30+.

Explore the full profile